Healthcare utilization and health-related quality of life of severe asthma patients in Singapore

Lim, Gerard Nicholas; Allen, John C.; Tiew, Pei Yee; Chen, Wenjia; Koh, Mariko Siyue

doi:10.1080/02770903.2022.2114086

Cited by 6 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of biologic therapies remains low in Singapore, contributed by the high cost and lack of reimbursement from the government, patient attitude, and perception of injection therapy. 4 …”

Section: Discussionmentioning

confidence: 99%

“…Severe asthma (SA) accounts for 3% to 4% of patients with asthma and is associated with poor quality of life, increased health care utilization, and socioeconomic burden. 1 , 2 , 3 , 4 , 5 As a complex and heterogeneous disease, it has different clinical courses, treatment responses, and airway inflammation. SA can be classified into 2 important endotypes on the basis of underlying inflammation: type 2 (T2) and non-T2 asthma.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Predictors of persistent poor control and validation of ASSESS score: Longitudinal 5-year follow-up of severe asthma cohort

Tiew,

Tay,

Chen

et al. 2024

Journal of Allergy and Clinical Immunology: Global

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Predictors of persistent poor control and validation of ASSESS score: Longitudinal 5-year follow-up of severe asthma cohort

Tiew,

Tay,

Chen

et al. 2024

Journal of Allergy and Clinical Immunology: Global

Self Cite

View full text Add to dashboard Cite

“…Despite this high OCS burden, only 17 patients (5%) had received biologics, primarily because of their high cost and lack of government reimbursement. 63…”

Section: Scs Usage Patterns In Asiamentioning

confidence: 99%

“…Finally, a recent study of 336 patients with severe asthma in Singapore revealed that patients received a mean of 2.6 courses of OCS per year with a mean cumulative dose of 570 mg (prednisolone equivalent). Despite this high OCS burden, only 17 patients (5%) had received biologics, primarily because of their high cost and lack of government reimbursement 63 …”

Section: Asthma Severity and Scs Usage In Asiamentioning

confidence: 99%

The burden of systemic corticosteroid use in asthma management in Asia

Dhar¹,

Rhee

Perng

et al. 2023

Respirology

View full text Add to dashboard Cite

For most patients, asthma can be effectively managed using inhaled medications. However, patients who have severe and/or uncontrolled asthma, or who experience exacerbations, may require systemic corticosteroids (SCSs) to maintain asthma control. Although SCS are highly effective in this regard, even modest exposure to these medications can increase the risk for long‐term, adverse health outcomes, such as type 2 diabetes, renal impairment, cardiovascular disease and overall mortality. Clinical and real‐world data from studies investigating asthma severity, control and treatment practices around the globe have suggested that SCS are overused in asthma management, adding to the already substantial healthcare burden experienced by patients. Throughout Asia, although data on asthma severity, control and SCS usage are limited and vary widely among countries, available data strongly suggest a pattern of overuse consistent with the broader global trend. Coordinated changes at the patient, provider, institutional and policy levels, such as increasing disease awareness, promoting better adherence to treatment guidelines and increasing availability of safe and effective alternatives to SCS, are likely necessary to reduce the SCS burden for patients with asthma in Asia.

show abstract

“…Although only a small portion of patients with asthma are affected by severe asthma, its burden is significant [ 7 , 8 ]. Thanks to the development of newer therapeutic agents, management of severe asthma has shown significant improvement in recent years [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Big Data Research on Severe Asthma

Kim,

Kim

2024

Tuberc Respir Dis

View full text Add to dashboard Cite

The continuously increasing prevalence of severe asthma has imposed an increasing burden worldwide. Despite the emergence of novel therapeutic agents, management of severe asthma remains challenging. Insights garnered from big data may be helpful in the effort to determine the complex nature of severe asthma. In the field of asthma research, a vast amount of big data from various sources, including electronic health records, national claims data, and international cohorts, is now available. However, understanding of the strengths and limitations is required for proper utilization of specific datasets. Use of big data, along with advancements in artificial intelligence techniques, could potentially facilitate the practice of precision medicine in management of severe asthma.

show abstract

Healthcare utilization and health-related quality of life of severe asthma patients in Singapore

Cited by 6 publications

References 40 publications

Predictors of persistent poor control and validation of ASSESS score: Longitudinal 5-year follow-up of severe asthma cohort

Predictors of persistent poor control and validation of ASSESS score: Longitudinal 5-year follow-up of severe asthma cohort

The burden of systemic corticosteroid use in asthma management in Asia

Big Data Research on Severe Asthma

Contact Info

Product

Resources

About